Nexentis Technologies (NXTS) Enterprise Value (2018 - 2026)
Nexentis Technologies (NXTS) posted Enterprise Value of -$5.5 million for Q2 2026, down 124.07% on a QoQ basis from -$2.4 million in Q4 2025, and down 103.39% year-over-year from $161.8 million in Q2 2025.
Analysis
Nexentis Technologies (NXTS) Enterprise Value (2018 - 2026) Analysis & Trends
Nexentis Technologies has reported Enterprise Value for 9 years, with the latest figure at -$5.5 million in Q2 2026.
- On a quarterly basis, Enterprise Value fell 103.39% year-over-year to -$5.5 million in Q2 2026; TTM through Jun 2026 was -$5.5 million, a 103.39% decrease from a year earlier, with the FY2025 full-year figure at -$2.4 million, down 105.1% from the prior year.
- Enterprise Value was -$5.5 million for Q2 2026 at Nexentis Technologies, down from -$2.4 million in the prior quarter.
- The five-year high for Enterprise Value was $4.0 billion in Q1 2022, with the low at -$5.5 million in Q2 2026.
- Average Enterprise Value over 5 years is $674.3 million, with a median of $145.5 million recorded in 2025.
- The largest YoY upside for Enterprise Value was 209.25% in 2025 against a maximum downside of 106.31% in 2025.
- Over 5 years, Enterprise Value stood at $641.2 million in 2022, then slumped by 87.6% to $79.5 million in 2023, then plunged by 39.7% to $48.0 million in 2024, then slumped by 105.1% to -$2.4 million in 2025, then slumped by 124.07% to -$5.5 million in 2026.
- The last three Enterprise Value figures came in at -$5.5 million (Q2 2026), -$2.4 million (Q4 2025), and -$3.0 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | Nexentis Technologies | 1.40 Mn | -7.60 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -5.49 Mn |
| Dec 31, 2025 | -2.45 Mn |
| Sep 30, 2025 | -3.03 Mn |
| Jun 30, 2025 | 161.83 Mn |
| Mar 31, 2025 | 145.45 Mn |
| Dec 31, 2024 | 47.96 Mn |
| Sep 30, 2024 | 48.02 Mn |
| Jun 30, 2024 | 52.33 Mn |
| Mar 31, 2024 | 131.35 Mn |
| Dec 31, 2023 | 79.54 Mn |
| Sep 30, 2023 | 178.68 Mn |
| Jun 30, 2023 | 1.12 Bn |
| Mar 31, 2023 | 771.38 Mn |
| Dec 31, 2022 | 641.23 Mn |
| Sep 30, 2022 | 1.72 Bn |
| Jun 30, 2022 | 2.38 Bn |
| Mar 31, 2022 | 4.00 Bn |
| Dec 31, 2021 | 2.75 Bn |
| Sep 30, 2021 | 4.38 Bn |
| Jun 30, 2021 | 4.18 Bn |